Shenzhen Beike Biotechnology Co. has received a $1.8 million grant to conduct a clinical trial of human umbilical cord mesenchymal stem cells (hUC-MSC) as a treatment for Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS) and other degenerative diseases. The grant was awarded by Jiangsu’s Department of Science and Technology. Beike Biotech’s partners in the project are Jiangsu University and Nanjing University’s Drug Tower Hospital. More details...